TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals announced a significant transaction involving its Executive Vice Chairman, Mazen Darwazah, who purchased 200,000 ordinary shares of the company at £17.56 each, totaling £3,512,000. This transaction, conducted on the London Stock Exchange, underscores the confidence of the company’s leadership in its market position and future prospects, potentially impacting stakeholder perception positively.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2500.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ strong financial performance and positive corporate events are the primary drivers of its stock score. Despite bearish technical indicators, the company’s solid valuation and strategic initiatives support a favorable outlook.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a global pharmaceutical company based in London, specializing in the development, manufacture, and marketing of a broad range of branded and non-branded generic medicines. The company focuses on providing high-quality medications across various therapeutic areas, serving markets in the United States, the Middle East, North Africa, and Europe.
Average Trading Volume: 517,496
Technical Sentiment Signal: Sell
Current Market Cap: £4.15B
For an in-depth examination of HIK stock, go to TipRanks’ Overview page.